Business

Recent analysis cites positive results of clinical psychedelic trials, coupled with a large amount of capital investment into biotech companies.

This week in psychedelic business news: Wesana teams up with MAPS, MindBio Therapeutics announces world-class research and drug development facility, and Awakn Life Sciences buys up ketamine clinics across the Nordics.

PSIL is the third psychedelics ETF to hit the markets after the launch of the world’s first psychedelic ETF earlier this year.

"HPPD is a discomfort. Some people have it for 10, 15, 20 years and they regret the day they did the drug that caused it," says the CEO of Ehave.

This week in psychedelic business news: major DMT development for stroke treatment; a propriety psilocybin formulation has potential to treat obesity; two more companies join the OTC Pink Market.

"Magic Truffle" producer and distributor Red Light Holland has had a very busy week, and Filament Health files a "milestone" patent.

Canadian psychedelics production company Red Light Holland announces largest legal sale and import of psilocybe truffles.

“The data suggests that we have a new drug that may be at least as effective, if not more effective, than 5-MeO-DMT and, more importantly, it looks like it is much safer," says Mindset Pharma CEO James Lanthier.

Everyday Dose is a tasty coffee replacement, which is easy to make and loaded with healthy benefits.

Delic establishes medical board to oversee psychedelic treatment protocols, cool new delivery systems investigated for psychedelics, and VR meets psychedelic therapies, finally. 

"The potential market for microdosing could be absolutely enormous because it is easier, more convenient, and more familiar," says Mindset Pharma CEO James Lanthier.

MindMed is currently conducting several clinical trials using psychedelic-inspired medicines, including studying LSD experiential therapy for anxiety, LSD microdosing for adult ADHD, and 18-MC for opioid withdrawal.

Clinicians are currently using TRIPP to help immerse patients into alternative realities and to support patients’ wellbeing before, during, and after ketamine-assisted therapy.

This week in psychedelic business news: More psychedelic clinical trials are green-lighted, new partnerships inked, and Beckley Psytech successfully completes upsized Series B financing. 

"A mushroom is not a pharmaceutical product," CEO Evan Levine stresses, and explains why his company's method of biologically engineering psilocybin is "cheaper, faster, greener."

The company will use proceeds of the fundraising round to complete its ongoing Phase 1B trial on low-dose psilocybin in patients suffering from a rare headache condition with no approved medications to treat it.

The Psychedelic Spotlight podcast guest also addresses criticism that she is a white woman working with sacred plant medicine, and how that inspired her next non-profit venture.

This week in psychedelic business news: Psychedelics in development to treat eye diseases and stroke; companies gear up for new clinical trials investigating psychedelics for general anxiety, chronic pain, and eating disorders.

Nova Mentis says that psilocybin could be a novel, first-in-class treatment for a brain disorder that leads to learning disabilities and behavioral problems.

According to the CDC, about 166 Americans die from TBI-related conditions each day.

The Vancouver-based company says it has overcome the challenges of natural extraction with its new technology, which can produce superior psilocybin at a lower cost.

Another clinic gets approval to conduct MDMA research, and new psychedelic research facilities open in Australia and the U.S., plus two game-changing psilocybin patents.

CEO Christopher Dawson and COO Andrew Galloway spent years working in clinical mental health treatment centers before betting big on psychedelics and ancient healing methods.

"This designation not only expedites our regulatory, clinical, and product development plans but also validates our belief in the potential of ketamine," says PharmaTher CEO Fabio Chianelli.

"Based on our research, we think we're able to get to psilocybin in fewer steps than any of the other published methods," says the company's CEO.

This week in psychedelic business news: More psychedelic-assisted therapy clinics, recruitment begins in early DMT trial, and Filament gets more Health Canada love.

The global supply chain of regulated psilocybin and ibogaine continues to grow as these Canadian companies beef up manufacturing efforts.

There is currently no known cure for the disease affecting 10 million people worldwide, but this psychedelics company thinks it has found a "viable candidate" using DMT.

This week in psychedelic business news: Psychedelics as a treatment for obesity and TBIs, plus another psychedelic company inches toward listing on NYSE American stock exchange.

And in other psychedelic stock news, Origin Therapeutics launches to make equity investments in emerging psychedelics-related companies.

Fungi bioscience company describes the project as “one of the most robust genetics research initiatives in the emerging psychedelics space to date."

The emerging wellness company aims to transform mental health and addiction treatments through the integration of psychedelic medicines and therapies.

Advisorshares Plant Medicine ETF will be listed on the NYSE Arca under the symbol PSIL.

This week in psychedelic business news: A generous donation to advance MDMA research, psilocybin for end-of-life anxiety, and provisional patents filed for synthesizing ibogaine.

The PsycheDev app guides users through intention setting, meditation, learning, contemplation and questioning, serving as a virtual facilitator and integration coach.

The OTCQB is a middle-tier market for entrepreneurial and development stage American and international companies.

Anthony Tennyson tells the Psychedelic Spotlight Podcast that his company has "discovered receptor sites that MDMA interacts with that we believe nobody else in the world knows about."

The deal creates Wesana Clinics, a chain of mental health facilities focused on delivering psychedelic-assisted psychiatric care, as well as data platform Wesana Solutions.

This week in psychedelic business news: It’s all about partnerships and acquisitions designed to advance psychedelic therapies for depression, suicidal ideation, pain, and more.

Cybin CEO says agreement "serves as a major step toward establishing a national distribution network for future psychedelic therapies."

NCT will utilize Numinus' expertise in psychedelic-assisted therapy to create a specialization in the application of psychedelics in the field of neurology

This week in psychedelic business news: Companies embrace the psychedelic aspects of VR, Braxia trains therapists in psychedelic best practices, and Allied gears up to provide its psychedelic formulation to PTSD patients.

Havn Life Sciences is expanding its psilocybin cultivation in Jamaica where the psychedelic mushrooms are legal to grow.

This week in psychedelic business news: A next-gen psychedelic for stroke care, a major merger, and two more companies list on NEO Exchange.

Former Food and Drug Administration division director Dr. Thomas Laughren has joined the psychedelic life sciences team at Cybin.

The Bob Marley-inspired line of psychedelic and functional mushrooms, Marley One, has officially launched through partner Silo Wellness.

German psychedelic pharmaceutical company Atai Life Sciences is valued at more than $3 billion after its IPO listing on the Nasdaq.

These psychedelic stocks are all publicly trading. Take a look at the companies leading the psychedelic medicine revolution.

This week in psychedelic business news: Patent progress for biosynthetic psilocybin, psychedelics for brain health, and psychedelic and cannabis companies team up in the name of research.

Atai Life Sciences is the latest psychedelic company to announce plans to IPO. The Peter Thiel-backed biotech startup is valued at more than $2 billion.

This week in psychedelic business news: An all-female biotech company, psychedelic-assisted psychotherapy for COVID front-liners, and more.

Psychedelic lifestyle brand Field Trip Health is now trading on the Toronto Stock Exchange under the symbol "FTRP".

GH Research is taking its psychedelic 5-MeO-DMT public on the Nasdaq with an IPO valued at more than $100 million.

Nue Life Health is a new therapy platform relying on AI and music as well as psychedelics for customized healing.

This week in psychedelic business: Mindset Pharma's new research, synthetic ibogaine, and the Western Hemisphere gets its first “smart shop.”

Defiance Next Gen Altered Experience ETF began trading Friday on the New York Stock Exchange under the symbol PSY.

This week in psychedelic business news: NeonMind's Medical Advisory Board, Mynd's public listing, and a new study supports novel use of DMT.

Psychedelic healing platform Field Trip Health has received conditional approval to uplist to the Toronto Stock Exchange.

Psychedelic drug development company Mynd Life Sciences has gone public on the CSE.

Cannabis-focused Enveric Biosciences will acquire Canadian psychedelic drug discovery platform MagicMed Industries.

This week in psychedelic business news: Therapists cleared to try MDMA, alternative medicine guru promotes psychedelic therapy, and the Swiss green-light new mescaline study. On the heels of the recently released trial data showing how MDMA-assisted…

Shark Tank investor Kevin O'Leary is a big fan of psychedelics. Here's everything you need to know.

PharmaDrug is bringing an online shop to the U.S. for sales of functional mushrooms and psychedelics once legal.

This week in psychedelic business news: Therapeutic uses of salvinorin A, a 5-MeO-DMT retreat, and World Boxing Council explores psychedelics.

Daniel Carcillo's psychedelic life sciences company is now trading on the Canadian Securities Exchange.

DMT-focused psychedelic therapy company Small Pharma is listing on the Canadian TSK Venture Exchange as it ramps up its offerings.

The psychedelic investment platform Clarify Pharma is expecting to go public on the AQSE with a valuation of £10.5 million.

Former heavyweight boxing champion Mike Tyson announced he's an investor in psychedelic wellness company Wesana Health.

This week in psychedelic business news: LSD for pain, DMT and organ transplants, Champignon Brands is now Braxia Scientific Corp, and more.

New Leaf Canada has received permission from Health Canada to build a first-of-its-kind laboratory to produce and study psilocybin and psilocin.

A new psychedelic VR experience is coming thanks to a partnership between Lobe Sciences and Virtual Psychedelics.

This week in psychedelic business news: Cybin’s experimental psychedelic takes aim at alcohol use disorder, Numinus seeks volunteers for its natural psilocybin extract, and another psychedelic company trades on Nasdaq.  Toronto-based…

MindMed will take its Kevin O'Leary-backed platform onto the Nasdaq Tuesday as only the 2nd psychedelic company to do so.

This week in psychedelic business news: Atai to raise $100 million, Silo's psilocybin nasal spray, and more.

Atai Life Sciences is now the second psychedelic company to list on Nasdaq, with plans to raise $100 million for its IPO.

This week in psychedelic business news:psilocybin’s genome sequencing explored, psychedelics meet artificial intelligence, and more.

GH Research closed a $125 million Series B financing round to fund the advancement of its 5-MeO-DMT treatment.

Toronto's Silo Wellness is now trading on the German Stock Exchange as demand for psychedelic treatments expands.

Former NHL player Daniel Carcillo's psychedelic startup Wesana Health is preparing to take the company public.

This week in psychedelic business news: a psilocybin delivery system for brain inflammation, a genetic test to predict your psychedelic-assisted therapy experience, and a potential first treatment for a debilitating form of schizophrenia.

Colorado-based Mydecine is launching four new psychedelic candidates for use in treating conditions like anxiety and depression.

This week in psychedelic business news: cannabis dives in, ketamine delivery, and psilocybin for autism anxiety.

Field Trip Health is brining psychedelics to the forefront of mental health wellness.

This week in psychedelic business news sees pharmaceutical giant Merck enter the arena, psilocybin research, and more.

This week in psychedelic business news, quick dissolve LSD, novel psychedelic molecules move into investigational studies, and more.

Patents of psychedelic substances are paving the way for new research and treatment options for a variety of diseases.

UK venture capital fund The Conscious Fund is working to make psychedelics more accessible and functional in various capacities.

This week in psychedelic business news, Canada expands legal distribution for psychedelics, therapeutic DMT stroke treatment, and more.

Numinus Biosciences has received expanded regulatory approval in Canada for psychedelic use and distribution.

The psychedelic drugs market is finding a strong base in North America, according to new data. The U.S. and Canada in particular are supporting its expansion.

Lumenate is an app that simulates a psychedelic experience without the need for illegal substances.

Defiance has launched the world's second psychedelics-focused ETF as investing in psychedelic therapy and treatment accelerates.

This week in psychedelic business news: two companies enter the Canadian Stock Exchange, AI comes to psychedelic treatment, and psilocybin comes to Brazil.

Biotech company Atai Life Sciences has earned a $2 billion valuation for its work in developing psychedelic treatments for mental health issues.

This week in psychedelic business news, Field Trip upsizes its bought deal, psilocybin truffles head to Brazil, another company goes public, and more.

NYU will open a $10 million psychedelic research center to further its work in using psychedelic substances to treat mental health issues.

This week in psychedelic business news: MindMed acquires a digital health company, Mindest Pharma goes public, new MDMA treatment for PTSD, and more.

This week in Psychedelic business news: MindMed has a new partner, Mydecine closes a funding round, and the world’s first legal psilocybin cultivation facility launches.

This week in psychedelic business news, Super Mario's magic mushroom gets a new use, Mindset files three patents, Bright Minds goes public, and more.

Clinical trials will look at the benefits of 5-MEO DMT as a treatment for relief from a number of mental health issues including depression.

The Horizons Psychedelic ETF launched on the Canadian NEO stock exchange last month. Here's what that means for the industry, and the future.

Canada's Red Light Holland is preparing to take its psilocybin truffles global as demand for psychedelics heats up.

This week in psychedelic business news, Psyence Group's psilocybin harvest, NeonMind's new CEO, and Mydecine sponsors new research.

This week in psychedelic industry news: the first psychedelic stock index, new products, mergers, and funds.

Wesana Health, founded by former NHL star Daniel Carcillo, has raised $4 million to continue its psychedelic research for traumatic brain injuries.

This week in psychedelic business news, IPOs, employee stock options, mergers, research, and more.

This week in psychedelic business news, Mydecine, Neon Mind, Ehave, and more.

NeonMind is the latest psychedelic company to go public. It's the first to launch on the Canadian Stock Exchange in 2021.

Taking psychedelics? There's an app for that. These companies are leading the way with trip guides, support, and more.

The momentum for psychedelics is snowballing, and 2021 is expected to be an even bigger and better year for the industry.

The UK gets its first psychedelic VC fund, psychedelic treatment for Parkinson's, and more business news.

This week in psychedelic business news: Motley Fool bets on MindMed, mushrooms go from Jamaica to Canada, and more.

Cybin Inc., has acquired the ketamine drug Spravato manufacturer Adelia Therapeutics in its first major acquisition.

This week in psychedelic business news: Numimus Wellness Inc. annouces a major partnership, Field Trip expands its investor relations, serial entrepreneur Peter Thiel invests in psychedelics for mental health treatment, and more. Numimus…

Billionaire tech investor Peter Thiel is the latest to join the booming psychedelic industry. The PayPal co-founder backed Berlin’s ATAI Life Sciences in a $125 million series C funding round. Thiel’s investment firm, Thiel Capital,…

Canadian pharmaceutical therapies company Cybin announced $45 million (CAD) in gross proceeds on a private placement of 60,000,000 subscription receipts as part of a new funding round. The company will use the funds to further expand its development…

Acclaimed integrative medicine pioneer, Dr. Andrew Weil, has joined the advisory board for psychedelic therapy platform Field Trip Health. “I am extremely pleased to be joining the medical advisory board at Field Trip,” Dr. Weil…

Another psychedelic therapy-based company has gone public. Toronto-based Field Trip Health Ltd., which operates the mobile therapy app Trip, is now trading on the Canadian Securities Exchange under the symbol FTRP. Psychedelic therapy for…

Just days after UK-based psychedelic developer Compass Pathways went public, New York-based MindMed has applied for a Nasdaq up-listing. The company, valued at $190 million,  is already listed on Canada’s NEO exchange. MindMed…

UK-based Compass Pathways led a groundbreaking IPO last week. Share prices spiked 71 percent to nearly $30 after the initial offering of 7.5 million shares, which launched at $17 each. Current value of the company based on its 34 million shares…

While they’ve historically brought the risk of long jail sentences, psychedelics are now bringing another long-term scenario: big-time investments. The potential for psychedelics in treating mental disorders such as depression, suicidal…

A first of its kind, The Psychedelic Medicine Association (PMA) is set to launch on September 29th. The association aligns medical establishments, patients, and industry leaders in the advancement of psychedelic therapy. “We want physicians…

Psychedelic drugs could soon have a standardized, and much faster delivery method with the announcement last month that ATAI Life Sciences AG and IntelGenx have entered into an agreement to develop polymeric film technologies. The…

Listening to Richard Carleton – the CEO of the Canadian Securities Exchange – talk about future investment opportunities in the psychedelic space, you come away with two thoughts: The differences between cannabis and psychedelics are stark,…

Vancouver-based Mydecine Innovations Group, Inc., has become the first company to earn the license to legally produce and distribute pharmaceutical-grade psilocybin in Canada, the company announced last month. Mydecine, which also has offices…

Better known for its psychedelic properties, Lysergic Acid Diethylamide (LSD) became extremely popular during the counterculture of the 1960’s. But it wasn’t only popular among the free-loving hippies... What most people fail to realize…